Evidence map›Paper›PMID 37936230›Full record

ArticleGenome medicine2023

Early detection of hepatocellular carcinoma via no end-repair enzymatic methylation sequencing of cell-free DNA and pre-trained neural network.

Zhenzhong Deng, Yongkun Ji, Bing Han, Zhongming Tan, Yuqi Ren, Jinghan Gao, Nan Chen, Cong Ma, Yichi Zhang, Yunhai Yao and 11 more

Abstract read
In one paragraph

Article in Genome medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Blood biomarkers of hepatocellular carcinoma: a critical review.Frontiers in cell and developmental biology · 2024
    Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Zhenzhong Deng *Department of Oncology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yongkun Ji *BamRock Research Department, Suzhou BamRock Biotechnology Ltd., Suzhou, Jiangsu Province, China.
Bing Han *Division of Hepatobiliary and Transplantation Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, the Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Zhongming Tan *Hepatobiliary Center, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China.
Yuqi Ren *College of Intelligence and Computing, Tianjin University, Tianjin, China.
Jinghan Gao *Department of Software Engineering, Tsinghua University, Beijing, China.
Nan Chen *National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China.
Cong MaSuzhou Known Biotechnology Ltd, Suzhou, Jiangsu Province, China.
Yichi ZhangDepartment of Transplantation, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yunhai YaoInfectious Disease Department, the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China.
Hong LuInfectious Disease Department, the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China.
Heqing HuangInfectious Disease Department, the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China.
Midie XuDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.
Lei ChenDepartment of Pathology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Leizhen ZhengDepartment of Oncology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jianchun GuDepartment of Oncology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. gujianchun@126.com.
Deyi XiongCollege of Intelligence and Computing, Tianjin University, Tianjin, China. dyxiong@tju.edu.cn.
Jianxin ZhaoDepartment of Interventional Medicine, the affiliated hospital of infectious diseases of Soochow University, Suzhou, 215131, Jiangsu Province, China. zhao13776@163.com.
Jinyang GuDepartment of Transplantation, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. gjynyd@126.com.
Zutao ChenInfectious Disease Department, the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China. 13004503747@163.com.
Ke WangHepatobiliary Center, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China. lancetwk@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEarly detection of hepatocellular carcinoma (HCC) is important in order to improve patient prognosis and survival rate. Methylation sequencing combined with neural networks to identify cell-free DNA (cfDNA) carrying aberrant methylation offers an appealing and non-invasive approach for HCC detection. However, some limitations exist in traditional methylation detection technologies and models, which may impede their performance in the read-level detection of HCC.

methodsWe developed a low DNA damage and high-fidelity methylation detection method called No End-repair Enzymatic Methyl-seq (NEEM-seq). We further developed a read-level neural detection model called DeepTrace that can better identify HCC-derived sequencing reads through a pre-trained and fine-tuned neural network. After pre-training on 11 million reads from NEEM-seq, DeepTrace was fine-tuned using 1.2 million HCC-derived reads from tumor tissue DNA after noise reduction, and 2.7 million non-tumor reads from non-tumor cfDNA. We validated the model using data from 130 individuals with cfDNA whole-genome NEEM-seq at around 1.6X depth.

resultsNEEM-seq overcomes the drawbacks of traditional enzymatic methylation sequencing methods by avoiding the introduction of unmethylation errors in cfDNA. DeepTrace outperformed other models in identifying HCC-derived reads and detecting HCC individuals. Based on the whole-genome NEEM-seq data of cfDNA, our model showed high accuracy of 96.2%, sensitivity of 93.6%, and specificity of 98.5% in the validation cohort consisting of 62 HCC patients, 48 liver disease patients, and 20 healthy individuals. In the early stage of HCC (BCLC 0/A and TNM I), the sensitivity of DeepTrace was 89.6 and 89.5% respectively, outperforming Alpha Fetoprotein (AFP) which showed much lower sensitivity in both BCLC 0/A (50.5%) and TNM I (44.7%).

conclusionsBy combining high-fidelity methylation data from NEEM-seq with the DeepTrace model, our method has great potential for HCC early detection with high sensitivity and specificity, making it potentially suitable for clinical applications. DeepTrace: https://github.com/Bamrock/DeepTrace.

Indexed as

Carcinoma, HepatocellularCell-Free Nucleic AcidsLiver NeoplasmsBiomarkers, TumorDNA MethylationDNA, NeoplasmHumansNeural Networks, ComputerBiomarkers, TumorCell-Free Nucleic AcidsDNA, NeoplasmCell-free DNACirculating tumor DNAEarly detectionEnzymatic conversionHepatocellular carcinomaNeural networkNo end-repair enzymatic methyl-seqRead levelWhole-genome methylation sequencing

Identifiers

PMID37936230
PMCPMC10631027

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.